Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials-Reference-Cited by-同舟云学术

Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials

Published:2019-07 Issue:7 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Jiao Yuanyuan¹,Moya Bartolome¹^ORCID,Chen Mong-Jen¹,Zavascki Alexandre P.²,Tsai Hsinyin¹,Tao Xun¹,Sutaria Dhruvitkumar S.¹,Louie Arnold³,Boyce John D.⁴^ORCID,Deveson Lucas Deanna⁴,Kim Tae Hwan¹⁵,Tsuji Brian T.⁶,Bonomo Robert A.⁷⁸⁹,Drusano George L.³,Bulitta Jürgen B.¹^ORCID

Affiliation:

1. Departments of Pharmaceutics and Pharmacotherapy & Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA

2. Department of Internal Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

3. Institute for Therapeutic Innovation, College of Medicine, University of Florida, Orlando, Florida, USA

4. Infection and Immunity Program, Monash Biomedicine Discovery Institute and Department of Microbiology, Monash University, Victoria, Australia

5. College of Pharmacy, Daegu Catholic University, Gyeongsan, Gyeongbuk, Republic of Korea

6. Department of Pharmacy Practice, University at Buffalo, Buffalo, New York, USA

7. Medical Service and GRECC, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA

8. Departments of Medicine, Pharmacology, Molecular Biology and Microbiology, Biochemistry, Proteomics and Bioinformatics, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA

9. CWRU-Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology (Case VA CARES), Cleveland, Ohio, USA

Abstract

There is a great need for efficacious therapies against Gram-negative bacteria. Double β-lactam combination(s) (DBL) are relatively safe, and preclinical data are promising; however, their clinical role has not been well defined.

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00425-19

Reference68 articles.

1. Clinical and Economic Impact of Common Multidrug-Resistant Gram-Negative Bacilli

2. Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America

3. Critical shortage of new antibiotics in development against multidrug-resistant bacteria—Time to react is now